Highly Anticipated FDA Decision Comes Just in Time for Back-to-School Season

The US Food and Drug Administration (FDA) has approved the first nasal spray for epinephrine supplied by San Diego-based ARS Pharma. The product, marketed as Neffy, will provide an alternative to traditional EpiPens, used to counteract allergic reactions, in children who weigh over 30 kg. An application to expand its use for children weighing under 30 kg is expected by the end of the year.